• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression

  • — 31 Oct, 2018
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
Extending Life in Triple Negative Breast Cancer with atezolizumab Immunotherapy
Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
00:00 / 6 mins
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed

Subscribe: Apple Podcasts | Spotify | Stitcher

MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer in the randomized phase three IMpassion130 trial reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.

https://www.nejm.org/doi/full/10.1056/NEJMoa1809615?query=featured_home

The experimental treatment also prolonged overall survival (OS) in patients who tested positive for PD-L1—the molecular target of atezolizumab.

Transformative

“For me this is practice-changing. This is a massive step. This is the first time—a clear improvement in overall survival, not just a marginal improvement. We see a transformative benefit of nearly ten months based on survival in the control group of only 15 months. So it’s more than a 50 per cent improvement in overall survival which is a very meaningful result for patients with this difficult-to-treat sub-type of breast cancer.”

So said first author of the IMpassion130 trial Peter Schmid MD PhD, Chair of Oncology at Barts Cancer Institute and Queen Mary University of London and Director of St. Bartholomew’s Breast Cancer Centre in London UK in conversation with the Audio Journal of Oncology.

You may also like...

  • Evangelos Terpos Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World 28 Jun, 2010
  • ASCO Audio Journal of Oncology – June 5th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 ASCO Audio Journal of Oncology – June 5th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 4 Jun, 2006
  • ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 5 Jun, 2006
  • Previous story Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
  • Next story BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with Chronic…
    • Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per…
  • Home
  • Oncology
  • AJO
  • PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.